高迁移率族蛋白B1及其在宫颈癌中的作用

doi:10.3760/cma.j.issn.1673422X.2017.03.020

摘要/Abstract

摘要： 胞外的高迁移率族蛋白B1（HMGB1）与晚期糖基化终末产物受体、Toll样受体、趋化因子CXCL12等相关受体及肿瘤信号调控通路作用引起持续的炎症反应，并最终促进肿瘤发生。在宫颈癌患者中，HMGB1的表达水平随宫颈癌变级别的升高而增加，HMGB1通过多种途径参与宫颈癌的发生发展、浸润和转移过程。应用RNA干扰技术可以抑制HMGB1基因表达，从而影响宫颈癌细胞的增殖、侵袭和分化，这为抗肿瘤药物的研发提供了新的思路。

关键词: HMGB1蛋白质, 宫颈肿瘤, 炎症, 抗肿瘤药

Abstract: Extracellular high mobility group box 1 (HMGB1) can cause persistent inflammation via related receptors and signal pathways such as receptor for advanced glycation endproduct, Tolllike receptors and chemokines 12, which results in tumorigenesis. In patients with cervical cancer, the expression of HMGB1 increases with the rising of malignant grade. HMGB1 participates in the genesis and development, invasion and metastasis of cancer through multiple processes. The expression of HMGB1 is inhibited by RNA interference, thus affects the invasion and migration of cervical cancer cell, which provides a new concept for the development of antineoplastic agents.

Key words: HMGB1 protein, Uterine cervical neoplasms, Inflammation, Antineoplastic agents

陈刚,庄昉成. 高迁移率族蛋白B1及其在宫颈癌中的作用[J]. 国际肿瘤学杂志, 2017, 44(3): 235-238.

Chen Gang, Zhuang Fangcheng. High mobility group box 1 and its role in cervical cancer[J]. Journal of International Oncology, 2017, 44(3): 235-238.

参考文献

［1］ Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease［J］. Mol Aspects Med, 2014, 40: 1-116. DOI: 10.1016/j.mam.2014.05.001. ［2］ Pilzweger C, Holdenrieder S. Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases［J］. Diagnostics (Basel), 2015, 5(2): 219-253. DOI: 10.3390/diagnostics5020219. ［3］ Lee SA, Kwak MS, Kim S, et al. The role of high mobility group box 1 in innate immunity［J］. Yonsei Med J, 2014, 55(5): 1165-1176. DOI: 10.3349/ymj.2014.55.5.1165. ［4］ Rabadi MM, Xavier S, Vasko R, et al. Highmobility group box 1 is a novel deacetylation target of Sirtuin1［J］. Kidney Int, 2015, 87(1): 95-108. DOI: 10.1038/ki.2014.217. ［5］ Beyer C, Pisetsky DS. Modeling nuclear molecule release during in vitro cell death［J］. Autoimmunity, 2013, 46(5): 298-301. DOI: 10.3109/08916934.2012.750297. ［6］ Spencer DM, Mobarrez F, Wallén H, et al. The expression of HMGB1 on microparticles from Jurkat and HL60 cells undergoing apoptosis in vitro［J］. Scand J Immunol, 2014, 80(2): 101-110. DOI: 10.1111/sji.12191. ［7］ Yamamoto K, Murata H, Putranto EW, et al. DOCK7 is a critical regulator of the RAGECdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells［J］. Oncol Rep, 2013, 29(3): 1073-1079. DOI: 10.3892/or.2012.2191. ［8］ Fucikova J, Kralikova P, Fialova A, et al. Human tumor cells killed by anthracyclines induce a tumorspecific immune response［J］. Cancer Res, 2011, 71(14): 4821-4833. DOI: 10.1158/00085472.CAN110950. ［9］ Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer［J］. Annu Rev Immunol, 2010, 28: 367-388. DOI: 10.1146/annurev.immunol.021908.132603. ［10］ Tsung A, Tohme S, Billiar TR. Highmobility group box1 in sterile inflammation［J］. J Intern Med, 2014, 276(5): 425-443. DOI: 10.1111/joim.12276. ［11］ Liu Y, Yan W, Tohme S, et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Tolllike receptor 9［J］. J Hepatol, 2015, 63(1): 114-121. DOI: 10.1016/j.jhep.2015.02.009. ［12］ Nagasawa T. CXCL12/SDF1 and CXCR4［J］. Front Immunol, 2015, 6: 301. DOI: 10.3389/fimmu.2015.00301. eCollection 2015. ［13］ UtoKonomi A, McKibben B, Wirtz J, et al. CXCR7 agonists inhibit the function of CXCL12 by downregulation of CXCR4［J］. Biochem Biophys Res Commun, 2013, 431(4): 772776. DOI: 10.1016/j.bbrc.2013.01.032. ［14］ Schiraldi M, Raucci A, Muoz LM, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4［J］. J Exp Med, 2012, 209(3): 551-563. DOI: 10.1084/jem.20111739. ［15］ Kew RR, Penzo M, Habiel DM, et al. The IKKαdependent NFκB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1［J］. J Immunol, 2012, 188(5): 2380-2386. DOI: 10.4049/jimmunol.1102454. ［16］ Lu B, Antoine DJ, Kwan K, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation［J］. Proc Natl Acad Sci USA, 2014, 111(8): 3068-3073. DOI:10.1073/pnas.1316925111. ［17］ Wagner KU, Schmidt JW. The two faces of Janus kinases and their respective STATs in mammary gland development and cancer［J］. J Carcinog, 2011, 10: 32. DOI: 10.4103/14773163.90677. ［18］ Livesey KM, Kang R, Vernon P, et al. p53/HMGB1 complexes regulate autophagy and apoptosis［J］. Cancer Res, 2012, 72(8): 1996-2005. DOI: 10.1158/00085472.CAN112291. ［19］孙小云, 张旭艳, 闫雪, 等. 宫颈癌组织中HMGB1、Notch1的表达及相关性［J］. 山东医药, 2015, 55(10): 30-32. DOI: 10.3969/j.issn.1002266X.2015.10.010. ［20］ Ohmori H, Luo Y, Kuniyasu H. Nonhistone nuclear factor HMGB1 as a therapeutic target in colorectal cancer［J］. Expert Opin Ther Targets, 2011, 15(2): 183-193. DOI: 10.1517/14728222.2011.546785. ［21］赵灵, 蔡红兵, 江大琼. 高迁移率族蛋白B1和基质金属蛋白酶9在宫颈鳞癌中的表达及其临床意义［J］. 武汉大学学报: 医学版, 2010, 31(3): 343-346. DOI: 10.14188/j.16718852.2010.03.029. ［22］ Sparatore B, Patrone M, Passalacqua M, et al. Activation of A431 human carcinoma cell motility by extracellular highmobility group box 1 protein and epidermal growth factor stimuli［J］. Biochem J, 2005, 389(Pt 1): 215-221. DOI: 10.1042/BJ20050053. ［23］李妍, 郝权. 高迁移率族蛋白1和肿瘤相关巨噬细胞与宫颈癌淋巴管密度的相关性研究［J］. 中国肿瘤临床, 2014, 41(4): 222-226. DOI: 10.3969/j.issn.10008179.20131738. ［24］ Sheng X, Du X, Zhang X, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA211, and CEA levels［J］. Croat Med J, 2009, 50(5): 455-464. ［25］ Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1related pathologies［J］. Pharmacol Ther, 2014, 141(3): 347-357. DOI:10.1016/j.pharmthera.2013.11.001. ［26］ Arumugam T, Ramachandran V, Gomez SB, et al. S100Pderived RAGE antagonistic peptide reduces tumor growth and metastasis［J］. Clin Cancer Res, 2012, 18(16): 4356-4364. DOI: 10.1158/10780432.CCR120221. ［27］邱媛媛, 郝权, 田菁, 等. RNA干扰抑制HMGB1基因表达对宫颈癌HeLa细胞生物学行为的影响［J］. 中国癌症杂志, 2010, 20(10): 739-744. ［28］ Feng L, Wu J. Effect of expression of high mobility group box1 inhibited by small hairpin RNA on the invasion and migration of human endometrial carcinoma HEC1A cells［J］. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2014, 39(1): 36-42. DOI: 10.11817/j.issn.16727347.2014.01.007. ［29］ Wu R, Wu J. Inhibition on the proliferation of human endometrial cancer cells by RNAi inhibiting HMGB1 gene expression and its possible molecular mechanism［J］. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2014, 39(7): 673-680. DOI: 10.11817/j.issn.16727347.2014.07.004.

[1]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[2]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[3]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[4]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[5]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[6]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[7]	何广思, 王军, 冯蒙蒙. 外周血细胞炎症标志物对晚期非小细胞肺癌免疫治疗预后的预测价值[J]. 国际肿瘤学杂志, 2023, 50(6): 321-327.
[8]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[9]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[10]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏. 复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[11]	马雪艳, 鲁历历, 孙鹏飞. 免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[12]	张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[13]	史英侠, 胡莉钧, 于静萍. 免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571.
[14]	彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.
[15]	王丽薇, 梁洪生, 杜松林, 陈志豪, 王晴, 高爱丽. 阿维菌素类药物在抗肿瘤方面的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 353-356.